Save up -80% on Apixaban
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Eliquis
|$458.07||60 tablets (5mg)|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Eliquis coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Apixaban every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Apixaban volume of distribution
Apixaban acts by directly inhibiting, in a reversible manner, free and clot-bound factor Xa to inhibit coagulation. Apixaban is absorbed in the stomach and small intestine. For doses up to 10 mg, the absolute bioavailability is about 50%.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Apixaban
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor (of both free and prothrombinase-bound FXa independently of antithrombin III) for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. FDA approved on December 28, 2012.
Apixaban mechanism of action
Apixaban acts by directly inhibiting, in a reversible manner, free and clot-bound factor Xa to inhibit coagulation.
Dosage forms of Apixaban
Bristol Myers Squibb Canada
Humans and other mammals
Indication of Apixaban
Apixaban is to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It has also been used to lower the risk of developing venous thrombosis post-orthopedic surgical procedures.
Toxicity of Apixaban
Premature discontinuation of any oral anticoagulant, including apixaban, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from apixaban to warfarin in clinical trials in atrial fibrillation patients. Apixaban increases the risk of hemorrhage and can cause serious, potentially fatal, bleeding. The drug should be discontinued if active pathological hemorrhage occurs. Epidural or spinal hematomas may occur in patients treated with apixaban who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity or spinal surgery. Apixaban should not be used in people with mechanical heart valves.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Apixaban on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.
Get lower price on Apixaban now!
What is a Eliquis?
Eliquis is a direct acting anticoagulant. Apixaban is a powerful direct inhibitor of FXa that reversibly and selectively blocks the active center of the enzyme. The drug is intended for oral administration. To implement the antithrombotic effect of apixaban, antithrombin III is not required. Apixaban inhibits free and bound FXa, as well as prothrombinase activity. Apixaban does not directly affect platelet aggregation, but indirectly inhibits thrombin induced platelet aggregation. By inhibiting the activity of FXa, apixaban prevents the formation of thrombin and blood clots.
As a result of the suppression of FXa, the values of the indicators of the blood coagulation system change: the prothrombin time is prolonged, the APTT is increased, and an increase in INR occurs. Changes in these indicators when using the drug in a therapeutic dose are minor and individual. Therefore, using them to assess the pharmacodynamic activity of apixaban is not recommended.
Inhibiting FXa activity with apixaban has been proven using a chromogenic test using Heparin Rotachrom. The change in anti-FXa activity is directly proportional to the increase in the concentration of apixaban in the blood plasma, while the maximum activity values are observed when the maximum concentration of apixaban in the blood plasma is reached. The linear relationship between concentration and anti-FXa activity of apixaban is recorded in a wide range of therapeutic doses of the drug. Changes in anti-FXa activity with changes in dose and concentration of apixaban are more pronounced and less variable than blood clotting rates.
In patients receiving apixaban after planned hip or knee joint arthroplasty, the maximum and minimum anti-FXa activity of the apixaban in equilibrium is 1.3 IU/ml (5/95 percentile – 0.67 IU/ml – 2.4 IU/ml) and 0.84 IU/ml (5/95 percentile – 0.37 IU/ml – 1.8 IU/ml), thus, the ratio of the maximum and minimum level of anti-FXa activity in the interval between doses of the drug does not exceed 1.6.
With apixaban therapy, routine monitoring of its anticoagulant effect is not required, however, performing the anti-FXa activity test of Rotachrom may be helpful in deciding whether to continue therapy. In comparison with warfarin with the use of the drug Eliquis, fewer bleeding is observed, including intracranial hemorrhage.